Pinsonault, Tony
June 2005
Pharmaceutical Representative;Jun2005, Vol. 35 Issue 6, p18
The article focuses on the value and growth of specialty pharmaceuticals in the U.S. Specialty pharmaceuticals are among the hottest products in U.S. healthcare today. They're attracting lots of attention in the media and the marketplace because they promise to effectively manage a variety of expensive chronic-care diseases and conditions. Specialty pharmacy came into its own in the early 1990s with the emergence of breakthrough oncology therapies and the new biotech industry. Specialty products offer new and effective treatments for diseases with few therapeutic options. In managed care, specialty drugs are typically managed and reimbursed outside of the pharmacy benefits, usually through the medical benefits.


Related Articles

  • Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities. Langley, P.C. // PharmacoEconomics;1999, Vol. 16 Issue 3, p211 

    From 1 January 1999, all requests by pharmaceutical manufacturers and others to Blue Cross and Blue Shield (BCBS) of Colorado and Nevada for the listing of new pharmaceutical products or any proposed change to the formulary status of an existing product must be accompanied by a submission which...

  • Pharmacy in position to act as coordinator. Gebhart, Fred // Drug Topics;6/10/96, Vol. 140 Issue 11, p108 

    Looks at the role that pharmacy and the pharmaceutical industry may play in making the American health care system a coherent one, as discussed by Michael Barberi at the 1996 Academy of Managed Care Pharmacy meeting. Conflicting policies and practices of players including employers, fiscal...

  • Outlook bright for 2004 blockbusters. Kirsche, Michelle L. // Drug Store News;1/19/2004, Vol. 26 Issue 1, p21 

    Presents an outlook for the pharmaceutical industry in 2004 in the U.S. Impact of the introduction of interim discount cards to the aged; Anticipation of increased prescription drug sales; Development of drugs for diseases associated with aging.

  • Drug Company Programs Help Low-Income Patients. Dummit, Laura A. // Consumers' Research Magazine;Jan2001, Vol. 84 Issue 1, p26 

    Describes the scope of drug companies medical programs for low-income patients in the United States. Amount of assistance they provide; Eligibility requirements for the program; Procedures for obtaining assistance. INSET: State Assistance Programs..

  • BTC class could equal bad business. Johnsen, Michael // Drug Store News;12/10/2007, Vol. 29 Issue 15, p38 

    The article examines the possible effects of the behind the counter (BTC) class of drugs on the pharmaceutical industry in the U.S. It was inferred that BTC class of drugs could create a new opportunity for drug manufacturers, especially if an extended exclusivity period was attached to a BTC...

  • Prescription Benefits Violate Drug Companies' Rights. Ghate, Onkar // Orange County Business Journal;8/12/2002, Vol. 25 Issue 32, p30 

    Argues against proposals to provide prescription drug benefits to the aged in the United States. Impact of prescription drug benefits on property rights of drug manufacturers; Hurdles faced by companies in developing drugs.

  • Study sees younger Americans using costlier prescription drugs. Levenson, Deborah // AHA News;05/15/2000, Vol. 36 Issue 19, p3 

    Deals with the findings on a study conducted by the researchers from Brandeis University and PCS Health Systems regarding pharmaceutical spending in the United States. Increase in drug spending; Factors that lead to spending increases; Recommendations from the Rx Health Value.

  • Lifesaver in the community. Stupak, Burt; Wood, William // Hill;9/26/2013, Vol. 20 Issue 108, p18 

    The author comments on the U.S. federal healthcare program called 340B which requires drug manufacturers that receive reimbursement from Medicaid and Medicare Part B to give a significant price break on outpatient medicines to certain safety net hospitals, health centers and clinics.

  • Patent expirations,, healthcare trends bode well for increased generic sales. Frederick, James // Drug Store News;3/5/2001, Vol. 23 Issue 3, p45 

    Provides information on the generic drug industry in the United States as of March 2001. Trends that support the optimism expressed in some quarters of the industry; Efforts to extend patent protection and maintain market leadership; Implications of the pressure to contain healthcare costs in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics